NR3C2 and type 2 diabetes mellitus: The FIDELIO-DKD study showed that finerenone, a non-steroidal selective mineralocorticoid receptor antagonist, lowered the risks of CKD progression and cardiovascular events in people with CKD and type 2 diabetes treated optimally with renin-angiotensin system blockade.